Combination chemotherapy with estramustine phosphate, ifosfamide and cisplatin for hormone-refractory prostate cancer.

@article{Kaku2002CombinationCW,
  title={Combination chemotherapy with estramustine phosphate, ifosfamide and cisplatin for hormone-refractory prostate cancer.},
  author={Haruki Kaku and Takashi Saika and Tomoyasu Tsushima and Atsushi Nagai and Teruhiko Yokoyama and Fernando Abarz{\'u}a and Shin Ebara and Daisuke Manabe and Yasutomo Nasu and Hiromi Kumon},
  journal={Acta medica Okayama},
  year={2002},
  volume={60 1},
  pages={
          43-9
        }
}
We evaluated the efficiency and toxicity of estramustine phosphate (ECT), ifosfamide (IFM) and cisplatin (CDDP) combination chemotherapy in twenty-one patients with hormone-refractory prostate cancer (HRPC), for which there is currently no effective treatment. Patients received a daily dose of 560 mg ECT in combination with 1.2 g/m2 IFM on days 1 to 5 and 70 mg/m2 CDDP on day 1. This combination therapy was given every 3 to 4 weeks. An objective response of more than 50% reduction in prostate… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer

BG Pienta KJ Redman, R Bandekar, +4 authors DC Smith
  • Urology
  • 1997
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1992
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
VIEW 2 EXCERPTS

[Chemotherapy for prostate cancer].

  • Nihon rinsho. Japanese journal of clinical medicine
  • 2000
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…